2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2035 Bone marrow fibrosis grade delineates distinct prognostic categories within type 1 CALR-mutated MF

Lucia Masarova, MD, Naveen Pemmaraju, MD2, Lingsha Zhou3, Sherry Pierce, BSN, RN4, Hagop Kantarjian, MD5, Guillermo Garcia-Manero, MD6, Prithviraj Bose, MD7
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: Outcomes in myelofibrosis (MF) are predicted by numerous models using combinations of clinical factors, karyotypic abnormalities, molecular mutations and bone marrow fibrosis grade, although the last has been minimally accounted for. While it has long been known that advanced fibrosis has a negative impact on outcome, its precise role in respect to MF “genotype” is not well defined.                     

Objective: We aimed to evaluate the impact of marrow fibrosis grade on outcome and correlations with genomic profiling of MF patients.

Methods: We performed a retrospective analysis of MF patients referred to our institution with available next generation sequencing (NGS; 81-gene myeloid panel in 85%) and bone marrow fibrosis grading (Thiele et al, 2005): severe (MF3) = reticulin with extensive intersections, coarse bundles of collagen +/- osteosclerosis. Analysis included fisher exact test or χ2 test for clinical characteristics, and Kaplan-Meier method with log-rank test for overall survival (OS).

Results: 792 patients (median age 67 years, range 20-92; 42% females) were included. MPN driver mutations identified: 129 CALR type 1 (16%), 67 CALR non-type 1 (8.5%), 452 JAK2 (57%), 57 MPL (7.2%) and 78 (11%) triple negative (TN). Additional non-driver mutations (AddMUT) (% within each MPN driver category) were found in 90 (69%), 47 (70%), 308 (68%), 42 (75%) of patients with CALR type 1, non-type 1, JAK2 and MPL.   

The most frequent AddMUT were ASXL1 (241, 30%); TET2 (147, 19%), RAS (61, 8%), SRSF2 (59, 7%), TP53 (47, 6%), U2AF1/SF3B1 (46, 6%/46, 6%), EZH2 (44, 5.6%), IDH1-2 (40, 5%). SRSF2 was more frequent in JAK2 [MF2] and less so in CALR type 1 [MF3] and TN [MF1-3]; EZH2 was more common in CALR non-type 1 [MF2] and RAS in CALR non-type 1 [MF3] and MPL [MF2-3].      

MF-1, MF-2 and MF-3 were equally distributed within MPN drivers groups: 16-47-38% in CALR type 1, 22-39-39% in CALR non-type 1, 18-40-42% in JAK2, 16-39-46% in MPL and 16-53-31% in TN.

2+AddMUT were increasingly more common with increased BM fibrosis in CALR type 1 (MF1-2-3: 10-22-41%), CALR non-type 1 (20-35-65%) and JAK2 (21-33-52%); they were comparable between MF 2 and 3 in MPL (11-41-35%) and TN patients (14-28-33%). 40% of all patients (317) carried 3+AddMUT with similar distribution across driver groups and MF grades.

Clinical characteristics (CALR type 1 vs CALR non-type 1 vs JAK2 vs MPL vs TN) significantly differed in the following (p < 0.05): CALR type 1 were the youngest (62 years vs 66 years median) MF1-2-3; CALR type 1 with MF-1 had fewer females (25% vs 45% median), MPL with MF-2 had the highest proportion of circulating (≥1%) blasts (64% vs 45% median).    

Patients with CALR type 1 had distinct OS (n of patients; median) based on MF1 vs MF2 vs MF3: MF1 (20; unreached) vs MF2 (60; unreached) vs MF3 (49; 86 months, NE), p 0.022 overall, each < 0.05. In the  remaining patients, OS between MF2 and MF3 was comparable: CALR type 2 (26-26; not reached for both, p 0.12), JAK2 (180-189; medians of 96 and 105, respectively, p 0.67); MPL (22-35; medians of 64 and 73 months, respectively; p 0.74) and TN (11-25; unreached and 61 months, respectively, p 0.66). In JAK2 patients, MF1 (83; unreached) compared favorably to MF2 (p 0.004) and MF2 or 3 (p 0.003); the trend was similar in the remaining patients, but not statistically significant.      

Subsequent analysis showed: 1/ OS in CALR type 1 was not stratified by the presence of AddMUT: MF1 / MF2 +AddMUT had unreached median OS; MF3 had the shortest OS with or without AddMUT (median 21 and 86 m, respectively). 2/ JAK2 MF2 or 3 +AddMUT (n 217) had significantly inferior OS (vs no AddMUT, n 98) with medians of 84 m vs unreached (p 0.012). Further comparison of these patients revealed that OS of JAK2 without AddMUT (n 144, median 141 months) was comparable to +1AddMUTwithoutHMR (n 88, median 118, 95% CI 98-137); and presence of HMR (n 183: ASXL1, EZH2, IDH, U2AF1 Q157, SRSF2: median 74, 95% CI 39-109) was comparable to +2AddMUTwithoutHMR (n 37; median 52 months, 95% CI 10-185).

Conclusion: In our comprehensive genomic and fibrosis grade analysis of a large MF cohort, we observed significant impacts of severe fibrosis and genomic complexity rather than specific mutations on the outcome of CALR type 1 and JAK2 mutated patients, respectively. These findings shed new light on the prognostic importance of bone marrow fibrosis grade (MF3) within the generally favorable risk CALR type 1 subgroup.    

Lucia Masarova, MD: Karyopharm - Honoraria; PharmaEssentia - Honoraria; GSK - Honoraria; Cogent - Honoraria; PharmaEssentia - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); MorphoSys - Membership on a Board/Advisory Committee